nct_id	official_title	first_received_date	aliskiren	irbesartan	olmesartan	telmisartan	valsartan	fu_days	minimum_age	maximum_age	gender_elig	hard_outcome	type_comparison	comparison_type	cmprsn	phase
NCT00034840	A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDISÂ® (Telmisartan 80 mg p.o. Once Daily) and DiovanÂ® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose	2002-05-02	0	0	0	1	1	49	18		All	0	diff_class7	cc7	C09CA03|C09CA07	Phase 4
NCT00095394	The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension	2004-11-03	0	1	0	0	0	119	18		All	0	diff_class3	cc3	C03	Phase 3
NCT00095550	The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension	2004-11-05	0	1	0	0	0		18		All	0				Phase 3
NCT00110422	Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome	2005-05-09	0	1	0	0	0	196	18		All	0	diff_class3	cc3	C03|C09	Phase 4
NCT00134160	The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk	2005-08-22	0	0	1	0	0	1092	65	84	All	1	diff_class3	cc3	C08	Phase 4
NCT00146341	An Eight Week Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.	2005-09-05	0	0	0	1	0	56	18	80	All	0	diff_class3	cc3	C03	Phase 3
NCT00151827	Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment	2005-09-08	0	0	1	0	0		18	75	All	0				Phase 3
NCT00154271	Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)	2005-09-08	0	0	0	0	1	84	18	75	All	0	diff_class3	cc3	C03	Phase 4
NCT00185133	A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of co-Administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension	2005-09-09	0	0	1	0	0		18		All	0	diff_class3	cc3	C08	Phase 3
NCT00170924	A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction	2005-09-10	0	0	0	0	1	266	45		All	0	placebo	cc_plac	C09CA03	Phase 4
NCT00170963	Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy	2005-09-10	0	0	0	0	1	84	18		All	0	diff_class3	cc3	C08	Phase 3
NCT00170989	Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg	2005-09-10	0	0	0	0	1	56	18	80	All	0	diff_class3	cc3	C03	Phase 3
NCT00171002	A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy	2005-09-10	0	0	0	0	1	84	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00190580	Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)	2005-09-11	0	0	0	0	1		20		All	0				Phase 4
NCT00168779	A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.	2005-09-12	0	0	0	1	1	56	18		All	0	placebo	cc_plac	C03AA03|C09CA03|C09CA07	Phase 4
NCT00185172	Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension	2005-09-12	0	0	1	0	0	84	18	75	All	0	placebo	cc_plac	C03AA03|C09CA08	Phase 3
NCT00219024	An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension	2005-09-12	1	0	0	0	0	56	18		All	0	placebo	cc_plac	C03AA03|C09XA02	Phase 3
NCT00219037	A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.	2005-09-12	1	0	0	0	0	487	18		All	1	diff_class3	cc3	C03	Phase 3
NCT00219063	A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension	2005-09-12	1	0	0	0	0	210	18		All	0	placebo	cc_plac	C09AA05|C09XA02	Phase 3
NCT00219076	A Six-week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg	2005-09-12	1	0	0	0	0	42	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00219102	A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg	2005-09-12	1	0	0	0	0	84	18		All	0	diff_class5	cc5	C09XA	Phase 3
NCT00219115	A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI â‰¥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg	2005-09-12	1	0	0	0	0	84	18		All	0	diff_class3	cc3	C08|C09	Phase 3
NCT00219128	An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension	2005-09-12	1	0	0	0	0	70	18		All	0	placebo	cc_plac	C09XA02	Phase 3
NCT00219141	A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension	2005-09-12	1	0	0	0	0	252	18	80	All	0	diff_class5	cc5	C09CA|C09XA	Phase 3
NCT00219154	A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension	2005-09-12	1	0	0	0	0	392	18		All	0	diff_class3	cc3	C03|C09	Phase 3
NCT00219167	An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference	2005-09-12	1	0	0	0	0	56	65		All	0	diff_class5	cc5	C09AA|C09XA	Phase 3
NCT00219180	An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension	2005-09-12	1	0	0	0	0	56	18		All	0	placebo	cc_plac	C09CA03|C09XA02	Phase 3
NCT00219193	An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg	2005-09-12	1	0	0	0	0	84	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00220220	Efficacy and Safety of Amlodipine Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy	2005-09-16	0	0	1	0	0	378	18		All	0	diff_class3	cc3	C08	Phase 3
NCT00220233	Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone	2005-09-16	0	0	1	0	0	364	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00239369	A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg	2005-10-13	0	0	0	1	0	98	18		All	0	same_class7	sm7	C03AA03|C09CA07	Phase 3
NCT00240448	A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDISÂ® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVANÂ® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension	2005-10-14	0	0	0	1	1	56	18		All	0	placebo	cc_plac	C09CA03|C09CA07	Phase 4
NCT00240474	A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)	2005-10-14	0	0	0	1	0	98	60		All	0	diff_class3	cc3	C08|C09	Phase 4
NCT00260923	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension	2005-11-30	1	0	0	0	0	56	18		All	0	placebo	cc_plac	C09XA02	Phase 3
NCT00262236	A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension	2005-12-02	1	0	0	0	0	84	18		All	0	diff_class3	cc3	C07|C09	Phase 3
NCT00264212	A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension	2005-12-09	0	1	0	0	0	84	60	90	All	0	diff_class3	cc3	C08|C09	Phase 4
NCT00273299	A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension	2006-01-04	0	0	0	0	1	70	18	80	All	0	diff_class3	cc3	C03	Phase 3
NCT00274599	A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDISÂ® (Telmisartan 40-80-80 mg, QD) and ALTACEÂ® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring	2006-01-10	0	0	0	1	0	98	19		All	0	diff_class5	cc5	C09AA|C09CA	Phase 4
NCT00274612	A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDISÂ®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of MicardisÂ® vs Ramipril Using ABPM	2006-01-10	0	0	0	1	0	98	18		All	0	diff_class5	cc5	C09AA|C09CA	Phase 4
NCT00277472	A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy	2006-01-12	0	0	0	0	1	196	18		All	0	diff_class3	cc3	C09	Phase 4
NCT00280540	A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension	2006-01-19	0	0	0	0	1	42	18		All	0	diff_class3	cc3	C03	Phase 4
NCT00281580	A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study	2006-01-24	0	0	0	1	0	56	18		All	0	placebo	cc_plac	C08CA01|C09CA07	Phase 3
NCT00281593	A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study	2006-01-24	0	0	0	1	0		18		All	0				Phase 3
NCT00294710	A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension	2006-02-18	1	0	0	0	0	392	18	80	All	0	diff_class3	cc3	C03|C09	Phase 3
NCT00311740	A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)	2006-04-04	0	0	0	0	1		20	80	All	0				Phase 3
NCT00316095	Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia	2006-04-19	0	0	0	1	0	56	18		All	0	diff_class3	cc3	C09|C10	Phase 3
NCT00327145	A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy	2006-05-16	0	0	0	0	1	112	18		All	0	same_class7	sm7	C08CA01|C09CA03	Phase 3
NCT00333489	A National, Multicentric and Comparative Study to Evaluate Efficacy and Tolerability of the Association of Valsartan and Amlodipine Versus Amlodipine Alone in the Treatment of Essential Arterial Hypertension - Stages I and II (Mild to Moderate).	2006-06-01	0	0	0	0	1		21	70	All	0				Phase 4
NCT00343551	A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension	2006-06-22	1	0	0	0	0	63	18		All	0	diff_class5	cc5	C09AA|C09CA|C09XA	Phase 3
NCT00344110	A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension	2006-06-22	1	0	0	0	0	56	20	75	All	0	placebo	cc_plac	C09CA01|C09XA02	Phase 3
NCT00350168	An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension	2006-07-07	0	0	0	0	1	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00353912	A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension	2006-07-17	0	0	0	0	1	84	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00368277	A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients â‰¥ 65 Years Old With Systolic Essential Hypertension	2006-08-22	1	0	0	0	0	252	65		All	0	diff_class5	cc5	C09AA|C09XA	Phase 3
NCT00386139	An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy	2006-10-09	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C03	Phase 3
NCT00387517	An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy	2006-10-11	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00400777	An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide	2006-11-15	0	0	0	0	1	119	18		All	0	diff_class3	cc3	C08	Phase 4
NCT00409643	A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients	2006-12-07	0	0	0	0	1	56	18		All	0	placebo	cc_plac	C08CA01|C09CA03	Phase 3
NCT00409760	A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.	2006-12-07	0	0	0	0	1	84	18		All	0	placebo	cc_plac	C08CA01|C09CA03	Phase 3
NCT00409851	A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.	2006-12-07	0	0	0	0	1		18		All	0				Phase 3
NCT00413049	A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Monotherapy	2006-12-18	0	0	0	0	1	56	18	85	All	0	diff_class3	cc3	C09	Phase 3
NCT00413413	A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.	2006-12-18	0	0	0	0	1	56	18	85	All	0	diff_class3	cc3	C08	Phase 3
NCT00425373	A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients	2007-01-22	0	0	0	0	1	56	20	80	All	0	placebo	cc_plac	C08CA01|C09CA03	Phase 2/Phase 3
NCT00425997	A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension	2007-01-23	0	0	0	0	1	70	18		All	0	diff_class3	cc3	C08|C09	Phase 4
NCT00439738	A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients	2007-02-23	0	0	0	0	1	112	40		All	0	diff_class3	cc3	C08|C09	Phase 4
NCT00454662	Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)	2007-03-30	0	0	1	0	0	1201.2	65	84	All	1	diff_class3	cc3	C03|C08	Phase 4
NCT00500604	A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg Versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension	2007-07-11	0	1	0	0	1	168	18	80	All	0	diff_class7	cc7	C09CA03|C09CA04	Phase 4
NCT00529451	An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension	2007-09-12	1	0	0	0	0	56	18		All	0	diff_class5	cc5	C09AA|C09XA	Phase 3
NCT00538486	Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)	2007-10-01	0	0	0	1	0	168	30	70	All	0	placebo	cc_plac	A10BA02	Phase 4
NCT00553267	An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy	2007-10-08	0	0	0	1	0	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00546754	BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With	2007-10-17	0	0	0	0	1	84	18	75	All	0	diff_class7	cc7	C09CA01|C09CA03	Phase 3
NCT00550953	Filtered Trial for Telmisartan 40mg Non-responder	2007-10-26	0	0	0	1	0	56	20		All	0	diff_class3	cc3	C08	Phase 3
NCT00558064	Filtered Trial for Amlodipine Non-responder	2007-10-29	0	0	0	1	0	56	20		All	0	diff_class3	cc3	C09	Phase 3
NCT00558428	An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy	2007-10-29	0	0	0	1	0	56	18		All	1	diff_class3	cc3	C09	Phase 3
NCT00591578	A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension	2007-12-27	0	0	0	0	1	168	18		All	0	diff_class7	cc7	C09CA03|C09CA09	Phase 3
NCT00614380	An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.	2008-01-28	0	0	0	1	0	238	18		All	0	same_class7	sm7	C08CA01|C08CA01|C09CA07|C09CA07	Phase 3
NCT00624052	An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension	2008-02-05	0	0	0	1	0	238	18		All	0	same_class7	sm7	C08CA01|C09CA07	Phase 3
NCT00631917	A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension	2008-03-03	1	0	0	0	0	378	50		All	0	diff_class5	cc5	C09AA|C09XA	Phase 4
NCT00687973	Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg	2008-03-20	0	0	0	0	1	168	18		All	0	diff_class3	cc3	C07|C09	Phase 4
NCT00649389	A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension	2008-03-28	0	0	1	0	0	84	18	80	All	0	diff_class3	cc3	C03|C08|C09	Phase 3
NCT00699192	A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily	2008-06-09	0	0	0	0	1	56	65		All	0	diff_class3	cc3	C09	Phase 3
NCT00696241	A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension	2008-06-10	0	0	1	0	0	42	18		All	0	placebo	cc_plac	C09CA08|C09CA09	Phase 3
NCT00696436	A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension	2008-06-10	0	0	1	0	1	42	18		All	0	placebo	cc_plac	C09CA03|C09CA08|C09CA09	Phase 3
NCT00698646	A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension	2008-06-13	0	0	0	0	1	112	70		All	0	diff_class3	cc3	C03|C09	Phase 4
NCT00705575	A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension	2008-06-23	1	0	0	0	0	84	18		All	0	diff_class3	cc3	C03	Phase 3
NCT00706134	An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal	2008-06-25	1	0	0	0	0	56	65		All	0	placebo	cc_plac	C09XA02	Phase 3
NCT00739973	An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension	2008-08-20	1	0	0	0	0	112	18		All	0	placebo	cc_plac	C08CA01|C09XA02	Phase 3
NCT00750113	A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.	2008-09-09	0	0	0	1	0	168	18	75	All	0	diff_class3	cc3	C08|C09	Phase 4
NCT00751751	Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.	2008-09-11	0	0	1	0	0	420	65		All	0	diff_class7	cc7	C09CA01|C09CA08	Phase 3
NCT00751829	Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension	2008-09-11	0	0	1	0	0	224	65		All	0	diff_class3	cc3	C08|C09	Phase 3
NCT00760266	An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension	2008-09-25	1	0	0	0	0	28	55		All	0	diff_class3	cc3	C09	Phase 4
NCT00765674	An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension	2008-10-02	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C03|C08|C09	Phase 3
NCT00777946	A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy	2008-10-20	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C08	Phase 3
NCT00778921	A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy	2008-10-23	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00797316	An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension	2008-11-24	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C03	Phase 4
NCT00809926	An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension	2008-12-16	1	0	0	0	1	56	18		All	0	diff_class5	cc5	C09XA	Phase 4
NCT00877929	An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.	2009-02-06	0	0	0	1	0	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00841672	An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients	2009-02-10	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00846365	A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCTÂ® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension	2009-02-13	0	0	1	0	0	56	18		All	0	diff_class5	cc5	C03AA|C03BA	Phase 3
NCT00853957	An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension	2009-02-26	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C09	Phase 4
NCT00860262	An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).	2009-03-11	0	0	0	1	0	56	18		All	0	diff_class3	cc3	C08|C09	Phase 3
NCT00865020	A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients	2009-03-17	1	0	0	1	0	91	18		All	0	diff_class5	cc5	C09CA|C09XA	Phase 4
NCT00872586	A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy	2009-03-27	0	0	1	0	0	84	18	75	All	0	diff_class3	cc3	C03	Phase 3
NCT00902304	A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy	2009-04-28	0	0	0	0	1	182	18		All	0	placebo	cc_plac	A10BA02	Phase 4
NCT00902538	Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone	2009-05-13	0	0	1	0	0	112	18		All	0	diff_class3	cc3	C03	Phase 3
NCT00923091	Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension	2009-06-16	0	0	1	0	0	378	18		All	0	diff_class3	cc3	C03	Phase 3
NCT00926289	A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)	2009-06-22	0	0	0	1	0	49	18		All	0	diff_class3	cc3	C03	Phase 4
NCT00931710	A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension	2009-07-01	0	0	0	0	1	84	18		All	0	diff_class3	cc3	C08	Phase 4
NCT00942994	An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension	2009-07-19	1	0	0	0	0	56	18		All	0	diff_class3	cc3	C03	Phase 4
NCT00949884	A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects	2009-07-29	0	0	1	0	0	56	18		All	0	placebo	cc_plac	C09CA01|C09CA08	Phase 4
NCT00956644	Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy	2009-08-10	0	1	0	0	0	77	18		All	0	diff_class3	cc3	C09	Phase 3
NCT00957554	Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy	2009-08-11	0	1	0	0	0	77	18		All	0	diff_class3	cc3	C08	Phase 3
NCT00993109	Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone	2009-10-09	0	0	0	0	1	84	18	75	All	0	diff_class3	cc3	C08	Phase 4
NCT00996281	A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension	2009-10-12	0	0	1	0	0	364	18		All	0	diff_class5	cc5	C03AA|C03BA	Phase 3
NCT01001572	A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy	2009-10-15	0	0	0	0	1	56	18	85	All	0	diff_class3	cc3	C08	Phase 3
NCT01033071	A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension	2009-12-14	0	0	1	0	0	84	18		All	0	diff_class5	cc5	C03AA|C03BA	Phase 3
NCT01042392	Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients	2010-01-01	1	0	0	0	0	56	18		All	0	diff_class5	cc5	C09AA|C09XA	Phase 4
NCT01071122	A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension.	2010-02-18	0	0	0	0	1	56	20	70	All	0	diff_class3	cc3	C08|C09	Phase 4
NCT01075698	A Trial of Telmisartan Prevention of Cardiovascular Disease	2010-02-24	0	0	0	1	0	1095.75	40	79	All	0	diff_class3	cc3	C09|non	Phase 4
NCT01101009	Efficacy of SevikarÂ® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-	2010-04-07	0	0	1	0	0	168	40	80	All	0	diff_class5	cc5	C09AA|C09CA	Phase 4
NCT01167153	A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment	2010-07-20	0	0	0	0	1	84	18	65	All	0	diff_class3	cc3	C09	Phase 4
NCT01237223	An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension	2010-10-29	1	0	0	0	0	56	20		All	0	placebo	cc_plac	C08CA01|C09XA02	Phase 3
NCT01508026	A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension	2012-01-09	0	0	0	0	1	112	18		All	0	placebo	cc_plac	C07AB12|C09CA03	Phase 3
NCT01518855	Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study)	2012-01-24	0	0	0	0	1	112	20	79	All	0	diff_class7	cc7	C08CA01|C08CA05	Phase 4
NCT01599104	A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension	2012-05-13	0	0	1	0	1	56	20		All	0	diff_class5	cc5	C09DX	Phase 3
NCT01615198	A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension	2012-06-06	0	0	1	0	1	98	65		All	0	diff_class5	cc5	C09DX	Phase 3
NCT01785472	A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension	2013-02-05	0	0	1	0	1	56	18		All	0	diff_class5	cc5	C09DX	Phase 3
NCT01838850	A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg	2013-04-22	0	0	1	0	0	112	20	75	All	0	diff_class3	cc3	C08	Phase 3
NCT01876368	A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan	2013-06-09	0	0	1	0	1	56	18		All	0	diff_class5	cc5	C09DX	Phase 3
NCT01928628	A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.	2013-08-21	0	0	0	0	1	56	20	75	All	0	diff_class3	cc3	C09	Phase 3
NCT01975246	An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg	2013-10-29	0	0	0	1	0	56	20	100	All	0	diff_class3	cc3	C03	Phase 3
NCT02172586	A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg Once Daily Compared With Losartan 100 mg Once Daily + HCTZ 12.5 mg Once Daily Over a Period of Further 12 Weeks in Mild to Moderate Hypertensive Patients (Grade 1 and Grade 2 WHO-ISH Guidelines 1999)	2014-06-20	0	0	0	1	0	168	18		All	0	diff_class7	cc7	C09CA01|C09CA07	Phase 4
NCT02175355	A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist MicardisÂ® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)	2014-06-25	0	0	0	1	0		35	84	All	0				Phase 3
NCT02177396	A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDISÂ® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.	2014-06-26	0	0	0	1	1		18		All	0				Phase 3
NCT02177409	A Prospective Randomized Open-Label, Blinded-Endpoint (PROBE) Trial Comparing MICARDISÂ® (Telmisartan) (80 mg QD) and Amlodipine (5 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.	2014-06-26	0	0	0	1	0	84	18		All	0	diff_class3	cc3	C08|C09	Phase 3
NCT02177435	An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.	2014-06-26	0	0	0	1	0	56	18	80	All	0	placebo	cc_plac	C03AA03|C09CA07	Phase 3
NCT02177461	A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension	2014-06-26	0	0	0	1	0	168	65		All	0	diff_class5	cc5	C09AA|C09CA	Phase 4
NCT02177500	An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg	2014-06-26	0	0	0	1	0	84	18	80	All	0	placebo	cc_plac	C03AA03|C09CA07	Phase 3
NCT02183701	A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring	2014-07-07	0	0	0	1	0	70	18		All	0	diff_class3	cc3	C03	Phase 3
NCT02200640	A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDISÂ® (Telmisartan) (40 & 80 mg QD) and COZAARÂ® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring	2014-07-24	0	0	0	1	0		18		All	0				Phase 4
NCT02200653	A Prospective, Randomised, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDISÂ® (Telmisartan) (40 or 80 mg p.o. Once Daily) and COZAARÂ® / LORZAARÂ® (Losartan) (50 or 100 mg p.o. Once Daily) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (TOPAS STUDY = Telmisartan and LOsartan ComParative ABPM Study)	2014-07-24	0	0	0	1	0	56	18		All	0	diff_class7	cc7	C09CA01|C09CA07	Phase 4
NCT02242318	A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of MicardisÂ® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring	2014-09-16	0	0	0	1	1	56	18		All	0	diff_class7	cc7	C09CA03|C09CA07	Phase 4
NCT02269176	12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients	2014-10-20	0	0	0	1	0	84			All	0	diff_class7	cc7	C09CA01|C09CA07	Phase 3
NCT02495324	A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension	2015-07-07	0	0	1	0	1		19	70	All	0				Phase 4
NCT02738632	Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination	2016-04-11	0	0	0	1	0	56	19		All	0	diff_class3	cc3	C03	Phase 3
